These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12379065)

  • 1. Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy.
    Bernard L; Vuagnat A; Peytavin G; Hallouin MC; Bouhour D; Nguyen TH; Vildé JL; Bricaire F; Raguin G; de Truchis P; Ghez D; Duong M; Perronne C
    Ann Intern Med; 2002 Oct; 137(8):656-9. PubMed ID: 12379065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summaries for patients. The relationship between levels of the anti-HIV drug indinavir in patients' hair and response to treatment.
    Ann Intern Med; 2002 Oct; 137(8):I48. PubMed ID: 12379092
    [No Abstract]   [Full Text] [Related]  

  • 3. Hair it is: the long and short of monitoring antiretroviral treatment.
    Gandhi M; Greenblatt RM
    Ann Intern Med; 2002 Oct; 137(8):696-7. PubMed ID: 12379072
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance.
    Servais J; Peytavin G; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
    AIDS; 2001 May; 15(7):941-3. PubMed ID: 11399971
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.
    van Rossum AM; Bergshoeff AS; Fraaij PL; Hugen PW; Hartwig NG; Geelen SP; Wolfs TF; Weemaes CM; De Groot R; Burger DM
    Pediatr Infect Dis J; 2002 Aug; 21(8):743-7. PubMed ID: 12192162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.
    Duval X; Mentré F; Lamotte C; Chêne G; Spire B; Dellamonica P; Panhard X; Salmon D; Raffi F; Peytavin G; Leport C;
    Ther Drug Monit; 2005 Feb; 27(1):63-70. PubMed ID: 15665749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
    Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
    Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in durability of treatment with initial PI-based regimens.
    Pérez-Elías MJ; Moreno A; Moreno S; Antela A; Dronda F; Muñoz V; Casado JL; Quereda C; Lopez D; Navas E
    HIV Clin Trials; 2003; 4(6):391-9. PubMed ID: 14628282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy.
    Urban AW; Bean P; Aziz D; Graziano FM; Neudeck BL
    Int J STD AIDS; 2003 Feb; 14(2):103-8. PubMed ID: 12662388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.
    Grabar S; Le Moing V; Goujard C; Leport C; Kazatchkine MD; Costagliola D; Weiss L
    Ann Intern Med; 2000 Sep; 133(6):401-10. PubMed ID: 10975957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
    Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
    HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination.
    Duval X; Peytavin G; Breton G; Ecobichon JL; Descamps D; Thabut G; Leport C
    AIDS; 2007 Jan; 21(1):106-8. PubMed ID: 17148976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART.
    Tozzi V; Bellagamba R; Castiglione F; Amendola A; Ivanovic J; Nicastri E; Libertone R; D'Offizi G; Liuzzi G; Gori C; Forbici F; D'Arrigo R; Bertoli A; Salvatori MF; Capobianchi MR; Antinori A; Perno CF; Narciso P
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):787-96. PubMed ID: 18507523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
    Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
    Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.
    Bongiovanni M; Bini T; Chiesa E; Cicconi P; Adorni F; Monforte d'Arminio A
    Antiviral Res; 2004 Apr; 62(1):53-6. PubMed ID: 15026202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.
    Yerly S; Rickenbach M; Popescu M; Taffe P; Craig C; Perrin L;
    Antivir Ther; 2001 Sep; 6(3):185-9. PubMed ID: 11808753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
    Demeter LM; Hughes MD; Coombs RW; Jackson JB; Grimes JM; Bosch RJ; Fiscus SA; Spector SA; Squires KE; Fischl MA; Hammer SM
    Ann Intern Med; 2001 Dec; 135(11):954-64. PubMed ID: 11730396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
    Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
    J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.